Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,540.00    9.00 (0.59%)
Bid:
1,535.00
Ask:
1,536.00
Spread: 1.00 (0.065%)
Market Cap: £3.24b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

17 May 2023 09:56

RNS Number : 7335Z
Hikma Pharmaceuticals Plc
17 May 2023
 

Hikma Pharmaceuticals PLC

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman and CEO

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman and CEO, who is a director and shareholder of Darhold.

c)

Price(s) and volume(s)

Price(s): £0.00p

Volume(s): 1,000,000

d)

Aggregated information

Aggregated volume: 1,000,000

Price: £0.00p

e)

Date of the transaction

16 May 2023

f)

Place of the transaction

Amman

 

 

 

 

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director and shareholder of Darhold.

c)

Price(s) and volume(s)

Price(s): £0.00p

Volume(s): 1,000,000

d)

Aggregated information

Aggregated volume: 1,000,000

Price: £0.00p

e)

Date of the transaction

16 May 2023

f)

Place of the transaction

Amman

 

 

Mohammed 'Ali' Al-Husry

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mohammed 'Ali' Al-Husry

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold.

c)

Price(s) and volume(s)

Price(s): £0.00p

Volume(s): 1,000,000

d)

Aggregated information

Aggregated volume: 1,000,000

Price: £0.00p

e)

Date of the transaction

16 May 2023

f)

Place of the transaction

Amman

 

Helen Middlemist

Deputy Company Secretary

17 May 2023

+44 (0) 2073992760

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGIGDULUBDGXR
Date   Source Headline
18th Mar 20087:02 amRNSPreliminary Results
4th Mar 20083:25 pmRNSVoting Rights and Capital
7th Feb 20087:00 amRNSVoting Rights and Capital
21st Jan 20082:58 pmRNSNotification of transaction
17th Jan 20082:02 pmRNSResult of Equity Issue
17th Jan 20087:01 amRNSTrading Update
17th Jan 20087:01 amRNSIssue of Equity
8th Jan 20083:46 pmRNSDirector/PDMR Shareholding
7th Jan 20081:17 pmRNSDirector/PDMR Shareholding
2nd Jan 200812:48 pmRNSDirector/PDMR Shareholding
2nd Jan 20089:49 amRNSDirector/PDMR Shareholding
17th Dec 20072:05 pmRNSDirector/PDMR Shareholding
14th Dec 20077:01 amRNSPre-close trading statement
10th Dec 20071:19 pmRNSHikma acquires APM
30th Nov 200711:18 amRNSVoting Rights and Capital
21st Nov 20073:56 pmRNSUpdate on Lisinopril Contract
31st Oct 20074:51 pmRNSLegal and General DTR Announc
15th Oct 20075:06 pmRNSDirector / PDMR Shareholding
8th Oct 20077:01 amRNSConditional cash offer
8th Oct 20077:00 amRNSBlock Listing of Shares
5th Oct 20077:00 amRNSBlocklisting - 6 Month Review
19th Sep 20074:22 pmRNSOption Exercise
14th Sep 20072:58 pmRNSDirector/PDMR Shareholding
11th Sep 20074:28 pmRNSNotification of transaction
7th Sep 20072:20 pmRNSNotification of transaction
5th Sep 20077:02 amRNSInterim Results 2007
9th Aug 20077:00 amRNSHikma enters Egyptian market
27th Jun 20077:01 amRNSPre-close trading statement
6th Jun 20071:45 pmRNSAGM Statement
6th Jun 20077:00 amRNSAGM Statement
14th May 20074:42 pmRNSAnnual information update
23rd Apr 20071:33 pmRNSHikma appoints new CEO
20th Apr 20072:57 pmRNSHikma acquires Thymoorgan
5th Apr 20079:50 amRNSBlock Listing 6-month review
5th Apr 20079:35 amRNSNotification of transaction
3rd Apr 20071:14 pmRNSLTIP awards
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200710:12 amRNSNotification of transaction
2nd Apr 200712:00 pmRNSNotification of transaction
2nd Apr 200710:27 amRNSNotification of transaction
2nd Apr 200710:26 amRNSNotification of transaction
2nd Apr 200710:26 amRNSVoting rights and capital
23rd Mar 200710:36 amRNSInterest in shares
22nd Mar 20077:03 amRNSFinal Results
26th Jan 200710:49 amRNSCompletion of Acquisition
22nd Jan 20077:02 amRNSHikma enters oncology market
18th Jan 20077:01 amRNSPre-close Trading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.